Robert LeBoyer
Stock Analyst at Noble Financial
(0.04)
# 4,537
Out of 4,556 analysts
416
Total ratings
28.1%
Success rate
-12.1%
Average return
Main Sectors:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NNVC NanoViricides | Reiterated: Buy | $6 | $1.52 | +294.74% | 2 | Jul 14, 2026 | |
| CVKD Cadrenal Therapeutics | Reiterated: Buy | $45 | $2.10 | +2,042.86% | 17 | Jul 14, 2026 | |
| MAIA MAIA Biotechnology | Reiterated: Buy | $14 | $1.30 | +976.92% | 23 | Jul 9, 2026 | |
| NRSN NeuroSense Therapeutics | Reiterated: Buy | $9 | $0.65 | +1,284.62% | 7 | Jul 2, 2026 | |
| UNCY Unicycive Therapeutics | Reiterated: Buy | $60 → $50 | $5.57 | +797.67% | 19 | Jul 1, 2026 | |
| ELDN Eledon Pharmaceuticals | Reiterated: Buy | $10 | $3.72 | +168.82% | 21 | Jun 23, 2026 | |
| GLSI Greenwich LifeSciences | Reiterated: Buy | $45 | $13.27 | +239.11% | 9 | Jun 2, 2026 | |
| GOVX GeoVax Labs | Reiterated: Buy | $10 | $0.936 | +968.38% | 25 | May 27, 2026 | |
| COCP Cocrystal Pharma | Reiterated: Buy | $6 → $10 | $0.9362 | +968.15% | 28 | May 27, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Buy | $12 | $0.86 | +1,295.35% | 5 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $5.94 | +236.70% | 10 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $5.29 | +51.23% | 7 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $1.29 | +830.23% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.05 | +391.80% | 9 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $70 → $37 | $10.59 | +249.39% | 30 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.086 | n/a | 5 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5423 | n/a | 24 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7155 | n/a | 36 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.118 | n/a | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $8.41 | n/a | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $9 | $1.11 | n/a | 11 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $0.71 | $0.09 | n/a | 2 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 → $20 | $2.55 | n/a | 10 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $27 | $0.0001 | n/a | 7 | Feb 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $15 | $4.02 | n/a | 8 | Jan 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $3.82 | n/a | 1 | Jan 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $14 | $1.79 | n/a | 7 | Jan 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $5.80 | n/a | 2 | Dec 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $1.34 | n/a | 6 | Dec 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.0001 | n/a | 5 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.44 | n/a | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $1.33 | n/a | 8 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $1.58 | n/a | 1 | Feb 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.96 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.65 | n/a | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $17 → $1 | $31.67 | n/a | 2 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.20 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0001 | n/a | 4 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.84 | n/a | 3 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.2672 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.799 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.24 | n/a | 2 | Feb 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $54 → $41 | $24.96 | n/a | 2 | Aug 5, 2016 |
NanoViricides
Jul 14, 2026
Reiterated: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Cadrenal Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: $45
Current: $2.10
Upside: +2,042.86%
MAIA Biotechnology
Jul 9, 2026
Reiterated: Buy
Price Target: $14
Current: $1.30
Upside: +976.92%
NeuroSense Therapeutics
Jul 2, 2026
Reiterated: Buy
Price Target: $9
Current: $0.65
Upside: +1,284.62%
Unicycive Therapeutics
Jul 1, 2026
Reiterated: Buy
Price Target: $60 → $50
Current: $5.57
Upside: +797.67%
Eledon Pharmaceuticals
Jun 23, 2026
Reiterated: Buy
Price Target: $10
Current: $3.72
Upside: +168.82%
Greenwich LifeSciences
Jun 2, 2026
Reiterated: Buy
Price Target: $45
Current: $13.27
Upside: +239.11%
GeoVax Labs
May 27, 2026
Reiterated: Buy
Price Target: $10
Current: $0.936
Upside: +968.38%
Cocrystal Pharma
May 27, 2026
Reiterated: Buy
Price Target: $6 → $10
Current: $0.9362
Upside: +968.15%
Cardiff Oncology
May 22, 2026
Reiterated: Buy
Price Target: $12
Current: $0.86
Upside: +1,295.35%
May 8, 2026
Reiterated: Buy
Price Target: $20
Current: $5.94
Upside: +236.70%
May 8, 2026
Reiterated: Buy
Price Target: $8
Current: $5.29
Upside: +51.23%
May 6, 2026
Reiterated: Buy
Price Target: $12
Current: $1.29
Upside: +830.23%
Apr 6, 2026
Reiterated: Buy
Price Target: $15
Current: $3.05
Upside: +391.80%
Mar 16, 2026
Reiterated: Buy
Price Target: $70 → $37
Current: $10.59
Upside: +249.39%
Jun 27, 2025
Rated: Hold
Price Target: n/a
Current: $0.086
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $0.5423
Upside: n/a
Feb 24, 2025
Rated: Hold
Price Target: n/a
Current: $0.7155
Upside: n/a
Jan 21, 2025
Rated: Hold
Price Target: n/a
Current: $0.118
Upside: n/a
Aug 16, 2022
Reiterated: Buy
Price Target: $5
Current: $8.41
Upside: n/a
Aug 15, 2022
Reiterated: Buy
Price Target: $8 → $9
Current: $1.11
Upside: n/a
Jun 1, 2022
Reiterated: Buy
Price Target: $0.71
Current: $0.09
Upside: n/a
May 14, 2021
Maintained: Buy
Price Target: $20 → $20
Current: $2.55
Upside: n/a
Feb 9, 2021
Maintained: Buy
Price Target: $18 → $27
Current: $0.0001
Upside: n/a
Jan 26, 2021
Maintained: Buy
Price Target: $6 → $15
Current: $4.02
Upside: n/a
Jan 25, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $3.82
Upside: n/a
Jan 24, 2021
Maintained: Buy
Price Target: $6 → $14
Current: $1.79
Upside: n/a
Dec 28, 2020
Downgraded: Hold
Price Target: n/a
Current: $5.80
Upside: n/a
Dec 24, 2020
Maintained: Buy
Price Target: $6
Current: $1.34
Upside: n/a
Nov 12, 2020
Reiterated: Buy
Price Target: $8
Current: $0.0001
Upside: n/a
Oct 5, 2020
Downgraded: Hold
Price Target: n/a
Current: $11.44
Upside: n/a
May 28, 2020
Maintained: Buy
Price Target: $5
Current: $1.33
Upside: n/a
Feb 18, 2020
Initiated Coverage: Buy
Price Target: $30
Current: $1.58
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $3.96
Upside: n/a
Nov 1, 2018
Rated: Hold
Price Target: n/a
Current: $2.65
Upside: n/a
Apr 10, 2018
Downgraded: Hold
Price Target: $17 → $1
Current: $31.67
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $2.20
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $8.84
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.2672
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $0.799
Upside: n/a
Feb 2, 2018
Rated: Hold
Price Target: n/a
Current: $2.24
Upside: n/a
Aug 5, 2016
Downgraded: Hold
Price Target: $54 → $41
Current: $24.96
Upside: n/a